Adenylyl cyclases (ACs) generate the second messenger cAMP from ATP. Mammalian cells
express nine transmembrane AC (mAC) isoforms (AC1–9) and a soluble AC (sAC, also …

While clinical gene therapy celebrates its first successes, with several products already
approved for clinical use and several hundreds in the final stages of the clinical approval …

Cyclic AMP is a universal second messenger, produced by a family of adenylyl cyclase (AC)
enzymes. The last three decades have brought a wealth of new information about the …

Adenylyl cyclases (ACs) catalyze the conversion of ATP to the ubiquitous second
messenger cAMP. Mammals possess nine isoforms of transmembrane ACs, dubbed AC1–9 …

A current challenge in cellular signaling is to decipher the complex intracellular
spatiotemporal organization that any given cell type has developed to discriminate among …

The feasibility of gene therapy for cardiomyopathy, heart failure and other chronic cardiac
muscle diseases is so far unproven. Here, we developed an in vivo recombinant adeno …

Gene therapy is proving likely to be a viable alternative to conventional therapies in
coronary artery disease and heart failure. Phase 1 clinical trials indicate high levels of safety …

Importance Gene transfer has rarely been tested in randomized clinical trials. Objective To
evaluate the safety and efficacy of intracoronary delivery of adenovirus 5 encoding adenylyl …

Rationale: Chronic elevation of 3′-5′-cyclic adenosine monophosphate (cAMP) levels
has been associated with cardiac remodeling and cardiac hypertrophy. However …

Congestive heart failure accounts for half a million deaths per year in the United States.
Despite its place among the leading causes of morbidity, pharmacological and mechanic …